AIM ImmunoTech | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.43.

EBIT: As of FY2026 Q2, the actual value is USD -3.489 M.

Cash and Cash Equivalents

AIM ImmunoTech Inc. reported $9.9 million in cash and cash equivalents as of June 30, 2026, a significant increase compared to approximately $3.0 million as of December 31, 2025.

Research and Development Expenses

Research and development expenses for the three months ended June 30, 2026, were approximately $589,000, which is lower than the $1.2 million reported during the same period in 2025.

General and Administrative Expenses

General and administrative expenses for the second quarter of 2026 were approximately $2.9 million, an increase from $1.5 million during the same period in 2025.

Net Loss

The net loss for the three months ended June 30, 2026, was approximately - $3.8 million, compared to a net loss of - $2.8 million for the second quarter of 2025.

Operational Highlights

AIM ImmunoTech Inc. completed patient enrollment and Ampligen dosing in the ongoing Phase 2 DURIPANC study for metastatic pancreatic cancer. The Company engaged Thermo Fisher Scientific’s PPD clinical research business to support the study design of a planned pivotal Phase 3 clinical trial in metastatic pancreatic cancer. Encouraging observations from Erasmus MC Cancer Institute included favorable safety findings, progression-free and overall survival trends, and consistently reported high quality of life among treated patients. AIM ImmunoTech Inc. strengthened its balance sheet through multiple financing transactions and successfully regained full compliance with NYSE American’s continued listing standards. The Company is also planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease, seeking non-dilutive funding opportunities.

Outlook / Guidance

AIM ImmunoTech Inc. anticipates DURIPANC data on clinical benefit in Q1 2027 and Overall Survival data in Q3 2027, expecting this data to amplify previous findings where Ampligen achieved a median Overall Survival of 34.8 months in late-stage pancreatic cancer compared to 12.5 months for historical controls. The Company plans to advance toward a planned Phase 3 development in pancreatic cancer. Additionally, it intends to pursue non-dilutive government funding for select infectious disease initiatives like Ebola.